Evaluating a new PET imaging method for renal cell carcinoma
Official title: A Prospective, Open-label, Single-center Study of CD70-Specific PET/CT Imaging for Non-invasive Diagnosis of Renal Cell Carcinoma
Run by Xijing Hospital · NCT06769893 · Data updated 2026-11-12
This study is testing a new type of PET scan to see if it can better diagnose and stage kidney cancer in patients who are suspected of having the disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, China, Shaanxi) |
| Status | Recruiting |
| Started | June 12, 2024 |
| Main results expected | April 1, 2025 |
| Study ends | November 7, 2025 |
| Registry record updated | January 10, 2025 |
| Trial ID | NCT06769893 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with a high suspicion of renal cell carcinoma based on conventional imaging.
✕Probably not a fit
Patients who have received prior anti-tumor treatments or have severe comorbid conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical study aims to assess the effectiveness of 68Ga-NOTA-RCCB6 PET imaging in diagnosing and staging renal cell carcinoma (RCC). It involves a prospective, open-label design with 60 patients suspected of having RCC, who will undergo PET/CT scans to evaluate the imaging protocol and diagnostic efficacy. The study will compare the results of this new imaging method with the established 68Ga-PSMA PET/CT imaging. The research includes a structured screening, baseline, and follow-up assessment period to ensure comprehensive data collection.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing and staging renal cell carcinoma, leading to better-targeted therapies.
How similar studies have gone: While similar imaging techniques have been explored, this specific approach using 68Ga-NOTA-RCCB6 PET imaging is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- The subject or legal guardian/caregiver must voluntarily sign the informed consent form. Ages 18 to 75 years old. Patients with suspected renal cell carcinoma based on conventional imaging studies, and who undergo 68Ga-PSMA PET/CT scanning. Patients with suspicious lymph nodes or distant metastases detected by conventional imaging or 68Ga-PSMA PET/CT. Willing and able to follow the study protocol. Exclusion Criteria: \- Patients who have received anti-tumor treatment prior to PET/CT scan. Suffer from severe other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, respiratory system, immunodeficiency and other serious diseases. Alternative subjects have contraindications to PET/CT scanning. Including but not limited to: those who cannot tolerate repeated intravenous injections; those who may be allergic to the drug and its components (including those with a history of severe allergies or allergic reactions, especially those with allergies to the tested drug); claustrophobia. In the past year, diagnosed with other malignant tumors; alternative subjects have undergone major surgery in the past 3 months; received experimental drug or device treatment with unclear effects or safety within the past month, or have participated in other interventional clinical trials. Pregnant or lactating women. Patients who are lost to follow-up. Other conditions that, in the researcher's assessment, may affect the study or make the subject unsuitable for participation in the study.
Where it's running
-
Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China
Xi'an, China, Shaanxi, China Recruiting
Study contacts
- Study coordinator: Ying Guo
- Email: guoying01192022@163.com
- Phone: 0086+15991459177
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cortical-plus-medullary versus medullary-only suturing for robot-assisted partial nephrectomy
This trial tests whether using only medullary stitches instead of both medullary and cortical stitches during robot-assisted partial nephrectomy helps protect kidney function and reduce operative time and blood loss for people with localized renal cell carcinoma.
-
Robot-assisted surgery for early-stage kidney tumors
This study is testing whether robot-assisted surgery without clamping the renal artery can safely and effectively treat early-stage kidney tumors while helping patients recover faster and keep their kidney function.
-
Testing LXP1788 Injection for Advanced Solid Tumors
This study is testing a new injection called LXP1788 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.